학술논문
Successful use of rituximab, an anti‐CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa.
Document Type
Article
Author
Source
Subject
*EPIDERMOLYSIS bullosa
*IGA glomerulonephritis
*MONOCLONAL antibodies
*RITUXIMAB
*
*
*
Language
ISSN
0307-6938
Abstract
The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: a network meta-analysis. We describe the successful use of rituximab for the treatment of IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. Successful use of rituximab, an anti-CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. [Extracted from the article]